GERALD V DOYLE
Dentist in Delaware
License number
Pennsylvania DS018397L
Category
Dentistry
Type
Dentist
Address
Address
2
Delaware
Wayne, PA 19087
Wayne, PA 19087
Organization information
See more information about GERALD V DOYLE at bizstanding.comGerald V Doyle DDS
129 Timothy Cir, Wayne, PA 19087
Categories:
Dentists
Phone:
(610) 828-0888 (Phone)
Additional:
Dentists
Gerald V Doyle Dr
129 Timothy Cir, Wayne, PA 19087
Industry:
Medical Doctor's Office Dentist's Office
Principal:
Gerald V. Doyle (Principal)
Gerald V. Doyle LLC
304 King Of Prussia Rd, Wayne, PA 19087
Industry:
Dentist's Office
Family And General Dentistry, Principal:
Gerald Doyle (Family And General Dentistry, Principal)
Professional information
Method For Predicting Progression Free And Overall Survival At Each Follow-Up Time Point During Therapy Of Metastatic Breast Cancer Patients Using Circulating Tumor Cells
US Patent:
2009006, Mar 5, 2009
Filed:
Aug 30, 2007
Appl. No.:
11/897504
Inventors:
William J. Allard - Harleysville PA, US
Gerald V. Doyle - Radnor PA, US
Daniel F. Hayes - Ann Arbor MI, US
Michael Craig Miller - Quakertown PA, US
Leon W.M.M Terstappen - Huntington Valley PA, US
Gerald V. Doyle - Radnor PA, US
Daniel F. Hayes - Ann Arbor MI, US
Michael Craig Miller - Quakertown PA, US
Leon W.M.M Terstappen - Huntington Valley PA, US
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials.
Pre-Clinical Method For Monitoring Serial Changes In Circulating Breast Cancer Cells In Mice
US Patent:
2009011, May 7, 2009
Filed:
Oct 20, 2008
Appl. No.:
12/254151
Inventors:
Gerald V. DOYLE - Radnor PA, US
International Classification:
A01N 1/02
US Classification:
435 2
Abstract:
The CellTracks® System provides a system to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. Pre-clinical studies of circulating tumor cells (CTC's) have been limited by the inability to repetitively monitor CTC's in animal models. The present invention provides a method to enumerate CTC's in blood samples obtained from living mice, using a protocol similar to an in vitro diagnostic system for quantifying CTC's in patients. Accordingly, this technology can be adapted for serial monitoring of CTC's in mouse xenograft tumor models of human breast cancer.
Gerald Vincent Doyle, Radnor PA
Specialties:
Dentist
Address:
304 King Of Prussia Rd, Radnor, PA 19087
Dr. Gerald V Doyle, Radnor PA - DDS (Doctor of Dental Surgery)
Specialties:
Dentistry
Address:
304 King Of Prussia Rd, Radnor 19087
(610) 688-1300 (Phone), (610) 688-2998 (Fax)
(610) 688-1300 (Phone), (610) 688-2998 (Fax)
Languages:
English
Method For Assessing Disease States By Profile Analysis Of Isolated Circulating Endothelial Cells
US Patent:
7901950, Mar 8, 2011
Filed:
Feb 2, 2007
Appl. No.:
11/701763
Inventors:
Mark Carle Connelly - Doylestown PA, US
Gerald V. Doyle - Radnor PA, US
Galla Chandra Rao - Princeton Junction NJ, US
Leon W. M. M. Terstappen - Huntingdon Valley PA, US
Gerald V. Doyle - Radnor PA, US
Galla Chandra Rao - Princeton Junction NJ, US
Leon W. M. M. Terstappen - Huntingdon Valley PA, US
Assignee:
Veridex, LLC - Raritan NJ
International Classification:
G01N 33/553, G01N 33/00, G01N 1/00, G01N 1/18
US Classification:
436526, 435 72, 435 724, 435372, 4352872, 436518, 436523, 436536, 436538, 436 10, 436 17, 436 18, 436 63, 436172, 436176, 436177, 422 73, 422 8205, 422101
Abstract:
Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.
Imaging Of Activated Vascular Endothelium Using Immunomagnetic Mri Contrast Agents
US Patent:
2010029, Nov 25, 2010
Filed:
Nov 1, 2007
Appl. No.:
12/445652
Inventors:
Gerald V. Doyle - Radnor PA, US
International Classification:
A61K 49/14, A61K 49/16
US Classification:
424 9323
Abstract:
Immunomagnetic nanoparticles are used as a contrast agent for enhancing medical diagnostic imaging such as magnetic resonance imaging (MRI). The present invention is directed to methods of making targeted MRI contrast agents from immunomagnetic particles, and to methods of using such MRI contrast agents. Typically, such targeted MRI contrast agents provide enhanced relaxivity, improved signal-to-noise, targeting ability, and resistance to agglomeration. Methods of making such MRI contrast agents typically afford better control over particle size, and methods of using such MRI contrast agents typically can afford enhanced blood clearance rates and distribution. The ability to use the contrast agents im MRI provides a tool in the diagnosis and treatment of several disease states.
Methods And Reagents For The Rapid And Efficient Isolation Of Circulating Cancer Cells
US Patent:
2002017, Nov 21, 2002
Filed:
Feb 19, 2002
Appl. No.:
10/079939
Inventors:
Leon Terstappen - Huntingdon Valley PA, US
Galla Rao - Princeton NJ, US
Shawn O'Hara - Ambler PA, US
Paul Liberti - Haverford PA, US
Steven Gross - Ambler PA, US
Gerald Doyle - Radnor PA, US
Galla Rao - Princeton NJ, US
Shawn O'Hara - Ambler PA, US
Paul Liberti - Haverford PA, US
Steven Gross - Ambler PA, US
Gerald Doyle - Radnor PA, US
International Classification:
G01N033/574
US Classification:
435/007230
Abstract:
Methods and compositions are provided for detecting circulating tumor cells and assessing said cells for alterations in tumor-diathesis associated molecules.
Method Of Assessing Metastatic Carcinomas From Circulating Endothelial Cells And Disseminated Tumor Cells
US Patent:
2009019, Jul 30, 2009
Filed:
Dec 22, 2007
Appl. No.:
12/004805
Inventors:
Mark Carle Connelly - Doylestown PA, US
Gerald V. Doyle - Radnor PA, US
Galla Chandra Rao - Princeton Junction NJ, US
Leon W.M.M. Terstappen - Amsterdam, NL
Gerald V. Doyle - Radnor PA, US
Galla Chandra Rao - Princeton Junction NJ, US
Leon W.M.M. Terstappen - Amsterdam, NL
International Classification:
A01N 1/02, C12Q 1/02
US Classification:
435 2, 435 29
Abstract:
A method for assessing cancer in test subjects is described based upon enumeration of circulating endothelial cells and/or disseminated tumor cells in a test subject. This method is used to quantify disseminated tumor cells. Correlations with circulating tumor cells provides prognostic information with high accuracy in assessing the risk of recurrence in patients with primary breast cancer.